Breaking News

AbbVie Completes ImmunoGen Acquisition

Gains flagship cancer therapy ELAHERE, a first-in-class antibody-drug conjugate approved for ovarian cancer.

AbbVie has completed its acquisition of ImmunoGen Inc., which is now part of AbbVie, gaining its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition expands AbbVie’s commercial and clinical presence in the solid tumor space. ImmunoGen’s follow-on pipeline of  next-gen ADCs complements AbbVie’s ADC platform and existing programs.
 
ELAHERE is a first-in-class ADC targeting folate receptor alpha (FRα) with a maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells. ELAHERE received U.S. FDA accelerated approval in 2022. ELAHERE is the first targeted medicine to show meaningful survival benefit in PROC. 
 
ImmunoGen’s pipeline includes a Phase 1 asset, IMGN-151, a next-gen anti-FRα ADC for ovarian cancer with the potential for expansion into other solid tumor indications. Pivekimab sunirine, currently in Phase 2, is an anti-CD123 ADC targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer, which was granted FDA breakthrough therapy designation for the treatment of relapsed/refractory BPDCN.
 
“Together with ImmunoGen, we have the potential to continue redefining the standard of care for those living with cancer,” said Robert A. Michael, president and chief operating officer, AbbVie. “The addition of ImmunoGen’s treatment for ovarian cancer will accelerate our ability to help patients today, expand our oncology pipeline and drive long-term revenue growth well into the next decade. I want to thank ImmunoGen for their efforts to advance science for patients and we look forward to welcoming our new colleagues to AbbVie.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters